Pulmonary hypertensionContinuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension
Section snippets
Patient Population
Patients with World Health Organization (WHO) Group I, Functional Class II or III with idiopathic PAH or PAH associated with connective tissue disease or anorexigens were enrolled in this study. Patients were either newly diagnosed or on stable PAH therapy for at least 3 months, but for whom additional PAH therapy was indicated. Additional screening study enrollment criteria were: (1) echocardiogram measurement consistent with PAH with an estimated RV systolic pressure >50 mm Hg; (2) no
Patient Population and Study Performance
Twenty-four patients with PAH were enrolled in the study and had an IHM implanted. Two patients were excluded from the subsequent data analysis; 1 patient did not require additional PAH-specific therapy and 1 patient died from right heart failure before obtaining the prescribed PAH therapy due to logistic reasons. Autopsy did not demonstrate any evidence of device-related complication. Patients' baseline characteristics are presented in Table 1. Seventy-three percent of patients had idiopathic
Discussion
The 6-minute walk distance is a frequently used end-point in clinical PAH trials and has been shown to correlate with outcome23 in these patients. However, it is possible that long-term outcome in PAH will be best preserved by targeting hemodynamic improvements to reduce risk of subsequent right ventricular failure. Non-invasive assessments of cardiac morphology (RV size, LV eccentricity) and hemodynamics, including cardiac output by echocardiography, may also prove to be useful parameters to
References (27)
- et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) The current treatment of pulmonary arterial hypertension: time to redefine success
Chest
(2006)- et al.
Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: 12-month follow-up in a multi-center trial of chronic heart failure patients
J Card Fail
(2002) - et al.
Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to oral endothelin-antagonist bosentan
J Heart Lung Transplant
(2005) - et al.
Continuous haemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost
Chest
(2003) - et al.
Continuous hemodynamic monitoring during incremental exercise in patients with pulmonary hypertension treated with inhalative prostanoids
Int J Cardiol
(2005) - et al.
Validity of the Minnesota Living with Heart Failure Questionnaire as a measure of therapeutic response to enalapril or placebo
Am J Cardiol
(1993) - et al.
Measurement of pulmonary artery diastolic pressure from a right ventricular pressure transducer in patients with heart failure
J Card Fail
(1996) - et al.
Measurement of pulmonary artery diastolic pressure from the right ventricle
J Am Coll Cardiol
(1995)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
Lancet
Prognosis of pulmonary arterial hypertension: ACCP evidence-based practice guidelines
Chest
Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension
J Heart Lung Transplant
Cited by (28)
Implantable Cardiac Rhythm and Hemodynamic Monitors
2016, Clinical Cardiac Pacing, Defibrillation and Resynchronization TherapyNovel technologies and devices for monitoring and treating pulmonary arterial hypertension
2015, Canadian Journal of CardiologyCitation Excerpt :In a small study by Kjellstrom et al., implantation of the CardioMEMS (St Jude Medical, Atlanta, GA) device in 10 patients with PAH allowed for closer monitoring of response to initiation of therapy and ambulatory monitoring with activity.27 Frantz and colleagues also explored the use of the Chronicle device (Medtronic, Minneapolis, MN) in a prospective, nonrandomized, multicentre study in 24 patients with PAH and correlated changes in hemodynamics with quality of life, changes in 6-minute walk distance, exercise tolerance, and brain natriuretic peptide.28 In an innovative study performed by Fruhwald et al., the Chronicle device was implanted in 5 patients with WHO Group 1 PAH and repeated short-term tests were performed with inhalation of iloprost, which demonstrated only short-term improvement in pulmonary hemodynamics.29
Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor
2015, Journal of Heart and Lung TransplantationHemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertension
2014, Journal of Cardiac FailureCitation Excerpt :A pressure sensor lead was placed with the tip in the right ventricle, preferably in a middle to high septal position. The pressure monitoring system has been described in detail previously.9–12 Measurement of heart rate (HR), right ventricular systolic (RVSP), diastolic (RVDP), and mean pulmonary arterial (MPAP) pressure were derived from each cardiac cycle and stored continuously as the median over a preprogrammed storage interval.
Pericardial effusions in pulmonary arterial hypertension: Characteristics, prognosis, and role of drainage
2013, ChestCitation Excerpt :Pericardiocentesis resulted in symptomatic and hemodynamic improvement in the setting of PAH in most patients. The latter was previously documented in a patient using an implantable hemodynamic device.24 The absence of acute right ventricular dilation or dysfunction was confirmed through dynamic echocardiographic imaging.
Conflicts of interest: R.P.F., R.L.B., R.C.B., R.J.B. and M.D.M. have received research support from Medtronic, Inc. B.K. and T.D.B. are employees of Medtronic, Inc.